[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-KYMR":3,"homepage-market-summary":31,"stock-news-KYMR":173},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"KYMR","2026-10-05",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Kymera Therapeutics, Inc. Common Stock","Nasdaq",null,"BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)","Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.","273","Watertown, MA",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":27,"avg_volume_52w":28,"range_52w_percent":29,"record_count":30},109.85,108.38,109.92,103.3301,107.39,2.46,2.29,729507.768767,15784,107.5732,130.050003,55.26,787848.6200757251,73,1539,{"status":32,"indices":33,"watchlist":76,"sectors":98,"benchmarks":153},"success",[34,42,49,56,63,69],{"symbol":35,"name":36,"price":37,"change":38,"pct_change":39,"is_up":40,"sparkline":41,"date":5},"SPX","S&P 500",7773.95,51.23,0.66,true,"0.0,8.3 2.3,10.7 4.6,13.5 6.9,9.4 9.3,11.7 11.6,13.9 13.9,16.0 16.2,10.6 18.5,9.8 20.8,2.6 23.2,2.6 25.5,6.3 27.8,6.4 30.1,3.9 32.4,7.7 34.7,8.5 37.1,9.7 39.4,8.8 41.7,5.2 44.0,2.0",{"symbol":43,"name":44,"price":45,"change":46,"pct_change":47,"is_up":40,"sparkline":48,"date":5},"NDX","NASDAQ 100",31076.44,268.51,0.87,"0.0,12.3 2.3,12.8 4.6,14.9 6.9,13.2 9.3,14.8 11.6,16.0 13.9,16.0 16.2,12.7 18.5,11.4 20.8,5.9 23.2,4.3 25.5,6.0 27.8,5.9 30.1,5.1 32.4,7.2 34.7,6.8 37.1,6.4 39.4,5.8 41.7,3.8 44.0,2.0",{"symbol":50,"name":51,"price":52,"change":53,"pct_change":54,"is_up":40,"sparkline":55,"date":5},"DJI","DOW JONES",51268,91,0.18,"0.0,2.0 2.3,5.0 4.6,7.4 6.9,3.6 9.3,4.7 11.6,7.2 13.9,11.9 16.2,9.5 18.5,10.2 20.8,7.5 23.2,8.9 25.5,11.5 27.8,12.7 30.1,9.1 32.4,11.7 34.7,12.7 37.1,16.0 39.4,15.8 41.7,14.0 44.0,13.3",{"symbol":57,"name":58,"price":59,"change":60,"pct_change":61,"is_up":40,"sparkline":62,"date":5},"COMP","NASDAQ Composite",27477.31,286.45,1.05,"0.0,11.9 2.3,13.4 4.6,15.0 6.9,12.7 9.3,14.1 11.6,16.0 13.9,16.0 16.2,11.9 18.5,10.9 20.8,5.3 23.2,4.2 25.5,7.1 27.8,7.0 30.1,5.8 32.4,8.1 34.7,8.3 37.1,7.8 39.4,7.7 41.7,4.7 44.0,2.0",{"symbol":64,"name":65,"price":66,"change":67,"pct_change":39,"is_up":40,"sparkline":68,"date":5},"RUT","RUSSELL 2000",2833.8,18.6,"0.0,2.0 2.3,5.4 4.6,7.8 6.9,6.8 9.3,8.3 11.6,10.0 13.9,11.0 16.2,9.7 18.5,10.8 20.8,9.6 23.2,8.2 25.5,12.6 27.8,12.9 30.1,12.6 32.4,14.2 34.7,15.1 37.1,16.0 39.4,15.1 41.7,13.0 44.0,11.4",{"symbol":70,"name":71,"price":72,"change":73,"pct_change":74,"is_up":40,"sparkline":75,"date":5},"VIX","CBOE VIX",15.52,0.21,1.37,"0.0,10.2 2.3,7.3 4.6,2.0 6.9,9.7 9.3,4.9 11.6,4.5 13.9,2.5 16.2,11.3 18.5,13.7 20.8,13.5 23.2,16.0 25.5,12.3 27.8,10.4 30.1,13.5 32.4,8.8 34.7,8.9 37.1,7.8 39.4,7.6 41.7,11.8 44.0,10.9",[77,84,91],{"symbol":78,"name":79,"price":80,"change":81,"pct_change":82,"is_up":40,"sparkline":83,"date":5},"NVDA","NVIDIA Corp",238.9,4.95,2.12,"0.0,16.0 7.3,12.2 14.7,13.8 22.0,12.6 29.3,10.1 36.7,7.0 44.0,2.0",{"symbol":85,"name":86,"price":87,"change":88,"pct_change":89,"is_up":14,"sparkline":90,"date":5},"AAPL","Apple Inc",332.89,-0.8,-0.24,"0.0,2.0 7.3,5.2 14.7,16.0 22.0,11.7 29.3,14.9 36.7,10.9 44.0,11.8",{"symbol":92,"name":93,"price":94,"change":95,"pct_change":96,"is_up":40,"sparkline":97,"date":5},"TSLA","Tesla Inc",378.69,8.1,2.18,"0.0,5.6 7.3,13.5 14.7,16.0 22.0,14.9 29.3,15.3 36.7,6.4 44.0,2.0",[99,104,109,114,119,124,129,134,139,144,148],{"name":100,"etf":101,"change":102,"price":103,"is_up":40},"Technology","XLK",0.56,200.93,{"name":105,"etf":106,"change":107,"price":108,"is_up":40},"Financials","XLF",0.73,53.88,{"name":110,"etf":111,"change":112,"price":113,"is_up":40},"Healthcare","XLV",0.72,167.37,{"name":115,"etf":116,"change":117,"price":118,"is_up":40},"Consumer Cycl","XLY",0.35,110.42,{"name":120,"etf":121,"change":122,"price":123,"is_up":40},"Consumer Staples","XLP",0.63,81.04,{"name":125,"etf":126,"change":127,"price":128,"is_up":40},"Energy","XLE",0.99,63.44,{"name":130,"etf":131,"change":132,"price":133,"is_up":40},"Industrials","XLI",0.09,170.1,{"name":135,"etf":136,"change":137,"price":138,"is_up":40},"Materials","XLB",1.31,49.5,{"name":140,"etf":141,"change":142,"price":143,"is_up":14},"Real Estate","XLRE",-0.34,40.67,{"name":145,"etf":146,"change":117,"price":147,"is_up":40},"Utilities","XLU",39.97,{"name":149,"etf":150,"change":151,"price":152,"is_up":40},"Comm Services","XLC",1.17,111.61,[154,159,164,169],{"ticker":155,"name":156,"price":157,"change":158,"is_up":40},"SPY","SPDR S&P 500 ETF",774.83,0.67,{"ticker":160,"name":161,"price":162,"change":163,"is_up":40},"QQQ","Invesco QQQ Trust",756.2,0.88,{"ticker":165,"name":166,"price":167,"change":168,"is_up":40},"DIA","SPDR Dow Jones ETF",512.11,0.2,{"ticker":170,"name":171,"price":172,"change":39,"is_up":40},"IWM","iShares Russell 2000",283.39,{"ticker":4,"count":174,"articles":175},15,[176,182,188,194,200,206,212,217,223,229,234,239,244,250,256],{"title":177,"link":178,"pubDate":179,"description":180,"source":181},"A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiogFBVV95cUxNaGFNNVlQemRMQWZweVNxaXdES1RUQ2pqUVZKanI5bm1KUGYwZ19VWDJVUHd6NzV0aVROSmtnNk9HREN6VGh2TG9FWmR3dngwQXJxSFpDd2xTdFhrWEZ4bDRqSWRKc0lOb2lBeEZoc2l1b2ZTWVAwSWFFbEJETlAtZmdWYU0yS1NpYkMxMUdUXzgtb0dfanBPaXRSTTlmTVZvbEE?oc=5","Thu, 01 Oct 2026 20:10:17 GMT","A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. stocktitan.net","stocktitan.net",{"title":183,"link":184,"pubDate":185,"description":186,"source":187},"Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock - MarketBeat","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi4wFBVV95cUxQWnFXbEtuZ05FcmpxcHRUTnpXU2pqaEY5aEtQVnpndmhtUnpPWXUtUGdMdjFkQ0loU0dJeXkteGhwYnFRTDdVWE9mclowLUNWZWdZRXpIbDF1cDhpMG5nLUpDMXBSSzNoZmNsUVZfbENMUkxnVU1CdXFOZFJETEZoYWhBUkp5dWVzekZ1NEZvSzJRUTZOZlExQk05czZZZzB1YUJ6bmV5WldiU1ZVbHJaRi1MOFdWUm1SV1pxTFpXNVUtaUJ2RWtTOFFmS09iZGxhMEN6enZHYXVtMmRfcTRoUUloRQ?oc=5","Thu, 01 Oct 2026 23:15:20 GMT","Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock MarketBeat","MarketBeat",{"title":189,"link":190,"pubDate":191,"description":192,"source":193},"Trading Systems Reacting to (KYMR) Volatility - Stock Traders Daily","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwAFBVV95cUxNbEVnR0pmbWd6NEtpY0d4QVhYbHYwRXNkMlFpSzFvOVF6bkdWel9DVTZXZkY4Tm1Tc2tVS2h2ZzZTeXhIc3hCR0JjSVNmWUtNTGlmM05sZnJlQ2xCc3lodkRHb1ZDa2V6VkQtM255S2hLZEZDQ0ZRTkNqZ0lGNmh2VTg1RUdkUWdrYUtsdzlRVUZXX00xc0dSMjN4SjlXMUVObmwtcHFvWl9sbXZNNG50RUU5dmh2RmxCb2tGSTgtM2g?oc=5","Fri, 02 Oct 2026 15:56:01 GMT","Trading Systems Reacting to (KYMR) Volatility Stock Traders Daily","Stock Traders Daily",{"title":195,"link":196,"pubDate":197,"description":198,"source":199},"KYMR Maintained by Citigroup -- Price Target Raised to $150 - GuruFocus","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMimgFBVV95cUxNdEdZdWh0VmZjY0FVUGwwd3hPWG1xUENDR2RWMmRNX3Y4OXNtX0d4STg5UVM1Ti1RQ2pJNThDRjBaeW4wWDRXZ0o0UmxhcTF5YmZPNHVCbVI3YmtoaW1HVDVwVV9BVWFUYUtfVUN2Ymw3THpYNjdXeVFwRXB0V3BJNVQzVnJzR2pvZTN6MFY1SHVUYkpkU1FKaG9n?oc=5","Mon, 05 Oct 2026 20:47:38 GMT","KYMR Maintained by Citigroup -- Price Target Raised to $150 GuruFocus","GuruFocus",{"title":201,"link":202,"pubDate":203,"description":204,"source":205},"Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock - Investing.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiyAFBVV95cUxOUVRGeVg2LUZQYXUxSlRXSDgydy13eGZwTHFtRmxHeXhMMnJmN3Vyc1hxb1VLSUdwT3E3RGNaWmpKdC1zTzVzb0dwRk9INi1GbXQ2cDRrdHM0a3lvRDZ3QlBjNlFTRVBVYkNYcHdNaUhxZ0V4ODQ0b3VaQ3V3R0tnNzI4TGhwMjhYUjN4QTNoZm14S3gwVFpLbk1RMWZsT05Ob1VSVExGeVJuREY4emNzNTNUaGEzU1RoOWxnV1JsbG1HZ203TWtPTA?oc=5","Thu, 01 Oct 2026 21:54:47 GMT","Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock Investing.com","Investing.com",{"title":207,"link":208,"pubDate":209,"description":210,"source":211},"J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitwFBVV95cUxPV3VXVVdwdHpLbWZxNkF1bWRROUtkclF0ZkNoQk15cVRuVWRQMnNsUElScUtWU190b3JHNWFLNU80cC1YSG5GeGx5bW9BYTlqVW1oNGdfSGtuNGxlaVRpU25xaEhUUThseFlTZmNrS3AyM2hHTGxkRVhhWmItbFBuSnBBazRydmFUcjNOaHEwdmlhV3l4NENLMjhKaXZUR3FCSGYycVN1UTJSTENETklsaHNLMWFFX3M?oc=5","Sat, 03 Oct 2026 13:23:07 GMT","J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 Moomoo","Moomoo",{"title":213,"link":214,"pubDate":215,"description":216,"source":181},"After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuAFBVV95cUxQWldJVF9vUmpmdWI5Rlo4MFkwZ09ZV1pxYlplMjJvRzR6amJzb29ROXoyb1BGTEQ3Z1p6N1E2TU1rSnZPLUstM1B1YnZQVktJemJTNVRqSEo2TFNkMXg3RmJpcDVzSU1ITW16cjdIdDJvXzRpb19SbkdUdmJJYl91OGtXVmF1U0NfMkdoVXFuZXN0SlZheU5yMVo5YU51QVp1dnBHRU0tUzN5bHNBSFZxZm90MjRjT3V5?oc=5","Thu, 01 Oct 2026 21:20:31 GMT","After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. stocktitan.net",{"title":218,"link":219,"pubDate":220,"description":221,"source":222},"FIG Stock Hits Record Low After RBC Capital Questions Monetization Of AI Features — But Retail Is Bullish - Stocktwits","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi-wFBVV95cUxOLWxuZUxKMEVPYTNaRzBjYTFvenpsd0VFNUk0amNMUEhFMFEtN3pKSmd6VlNwNjBoUjdJV3VYWlowX09VVVJGYVJUdDluRzUzWVExYkY0SWdhSG1vYlBUUFRxQkY3TUJhZFBUR0lJSElrOTF3aElLeUVSb1RPc2xJU3E5dGxoeS1tdXlHYmdCMk5aWmtrYUVLS3ZVNXN5Z2lUZGhvOFp1RnVHemR4dlF5b3F2RU1rcjJlN3R4T0JlMFdZem1TNnhQMDFPM3VNZ2ZjY1R1UEpfQnZFcnRBSHpldHNOcXdfVFRHcUFIcWl0dkp6MDlVQnpSLUxfWQ?oc=5","Tue, 06 Oct 2026 02:44:10 GMT","FIG Stock Hits Record Low After RBC Capital Questions Monetization Of AI Features — But Retail Is Bullish Stocktwits","Stocktwits",{"title":224,"link":225,"pubDate":226,"description":227,"source":228},"B.Riley keeps Buy rating for Kymera Therapeutics stock - AD HOC NEWS","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiswFBVV95cUxPVkxKVWZTcHphRERIOTR6OXY2NWpkRGV4TFoxVHB6WDlvSE5VbnloNVRTVmI1RXNQbHJqbFBmSFY2dXNteEpjUWZHNVoxdFFCX0pVR3RYdGM5TzFqQWlUTWN2WS1QY0RtS096WDdDUWdqN2VZWFExdU50SVBfMkVrWkJ2UW9tV3RpUmdFWC0xVHRtSmRkQ2t5LUQ4LWFnTV90WWo2UVlidTBaNkZ1R3hiUGJlQQ?oc=5","Fri, 02 Oct 2026 11:32:32 GMT","B.Riley keeps Buy rating for Kymera Therapeutics stock AD HOC NEWS","AD HOC NEWS",{"title":230,"link":231,"pubDate":232,"description":233,"source":205},"Piper Sandler reiterates Kymera Therapeutics stock rating at $140 - Investing.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxNRlc1OUQ4U2NpeWwyZTJkcjZHWDVteWtxeEFaVURNV2RhVE1sRzRIaFAtZ2ExX2lOaVd5MEdWbjNKSjVGaWlJekxWakhzTGU3UkVWZGFQTDBuZkp6X0QybE1TZWRZMXlsMVhtUWExcjhoWnU3Y2gtZnMyNEYxelNJLXpSc0hrSElEbzh3Z2pHUGIxMWxCVjhaLTRiOG12TzNPa0Z4ZWptUkd3YzVrekd0aEdPUVlZYnVIWWRzNFhpd05FZw?oc=5","Wed, 23 Sep 2026 07:00:00 GMT","Piper Sandler reiterates Kymera Therapeutics stock rating at $140 Investing.com",{"title":235,"link":236,"pubDate":237,"description":238,"source":205},"Goldman Sachs resumes Kymera Therapeutics stock coverage - Investing.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitwFBVV95cUxNWFMzb1pXQXdCb2RUR0QwMnZob0RvUE1SSHBDZHRKMEljWXg0WnkwUlREX29RZ2tzRUtpQklCREpwOWZ1bE1McXdLd0VCRWNSWU9XRXMwZHlaMDY5bVBHSnZURDVoU2M4bTRDOG1KMHdUVUtKRnNwdFpTcGEzTFJsZzdMOUlESmpTVGtENzA0bl90cGFPdzFCZ3MtUVVwb2pIQjVhNlV4VTR0NFpYVF9pZzktRWpoenM?oc=5","Thu, 24 Sep 2026 07:00:00 GMT","Goldman Sachs resumes Kymera Therapeutics stock coverage Investing.com",{"title":240,"link":241,"pubDate":242,"description":243,"source":228},"Kymera Therapeutics stock reports 465.2 percent revenue growth - AD HOC NEWS","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivgFBVV95cUxPX0tRdHhLYzZGTmYtcEJKeC1GUHpSSkhrREducWpFWUtNNFV4cmZNdDRlaUd2Mzc3TnJYYXRZdzFPcFhORlpHUXlrZDNjSE5PV2NCdU5weF9aZk1hR082SldGLVNTVE82WW9SOXZWcWJ3VGhIMmhmaXZqWW5FZ3UtYnduRTloSkxBeVlra0RQZTkzMTNfMFFQMG91bnJaYjlLR3dUbW9Vay13VG9qcEpfcjFWSVJMR2p3Ylo0LTNn?oc=5","Wed, 30 Sep 2026 22:27:33 GMT","Kymera Therapeutics stock reports 465.2 percent revenue growth AD HOC NEWS",{"title":245,"link":246,"pubDate":247,"description":248,"source":249},"B.Riley reiterates Kymera Therapeutics stock rating on new trial data - Investing.com Nigeria","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiyAFBVV95cUxPaDY4SGdEbW5lQTgzU0ZZSzBaenpmQmpzR1BuTGxISmlUc0ZyUXFUYVhyY1pQRHlUMktTNF9KeEJXb0lGcXRPY1I2SWNQWUN4Y1ZEcHRpTjN5SmtzWUpHSERJOGljY2YtVHQ2N2FnVExGczVqd1hHQUJuNl9CdzR1dnZKNUJRb0NPTjhPVkZpc0JYQ19WTU1icUJmdi1pdDFydHZFdzBwNDNxZzlJemlxUXJXanpMS2tFY0I3OTN1MTVJVXVKSXZnSg?oc=5","Thu, 01 Oct 2026 11:01:39 GMT","B.Riley reiterates Kymera Therapeutics stock rating on new trial data Investing.com Nigeria","Investing.com Nigeria",{"title":251,"link":252,"pubDate":253,"description":254,"source":255},"Citi raises Kymera Therapeutics stock price target on drug potential By Investing.com - Investing.com South Africa","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiyAFBVV95cUxOdUp0N3E0YUw0Rkk0MjhYZHFqNkpkbUQ0WTdNVkxIbWxtc1NqUXhhSGJiZms2UlJhUm5rLVRUc2Z6dEx2YUxFZVR0MVdCN0hKcWlCajNnekFYcXZjVDN2SjcyX1I2UXpGVmtUVHcwZm9vSHQxdERUbUdhQTFtOUVaUDI0Uk91eEtnbEJzRmRlQ0l0bHdoampQOXpnXzNvUWpXZFZkdVJpNHN1VS1rUG04ZFRZSlNGVzFZa2p5Z29neHZTVDl1LXg4UA?oc=5","Mon, 05 Oct 2026 10:21:07 GMT","Citi raises Kymera Therapeutics stock price target on drug potential By Investing.com Investing.com South Africa","Investing.com South Africa",{"title":257,"link":258,"pubDate":259,"description":260,"source":261},"Kymera Therapeutics Slides After Red‑Hot Drug Optimism - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMilwFBVV95cUxNZFhENzBmUWhHUmZVaHhidlIxY2V6MWhvSGloWm9rUmhVRkJGcUVxVGNFc09raXRDbEVJejUxZ3Y3TDE3b3lMYUI0cTJSWGJDRndTaVM4WUZDOHQ3ak1mUmlDWHNHd3VDR3pldUxGVlJJbVg3bmRvdFdBZzYtVnpOTWQtWVZuMWdTMHlfUUoxNFlyZ21VYXJ3?oc=5","Thu, 01 Oct 2026 08:46:24 GMT","Kymera Therapeutics Slides After Red‑Hot Drug Optimism TipRanks","TipRanks"]